Severe intellectual disability-progressive spastic diplegia syndrome
MONDO:0014035Severe intellectual disability-progressive spastic diplegia syndrome is a rare condition that has been described in a few people with severe intellectual disability. Other signs and symptoms include progressive microcephaly (very small head); ataxia (lack of coordination); spasticity ; and/or skin, hair and mild facial anomalies. It is caused by changes (mutations) in the CTNNB1 gene and it is inherited in an autosomal dominant fashion. Treatment is based on the signs and symptoms present in each person.
Also known as: CTNNB1 syndrome, MRD19, autosomal dominant intellectual disability 19, intellectual disability, autosomal dominant type 19, mental retardation, autosomal dominant type 19, neurodevelopmental disorder with spastic diplegia and visual defects, severe intellectual disability-progressive spastic diplegia syndrome, CTNNB1-related intellectual disability
4 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug FOG-001 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…
Phase: PHASE1, PHASE2 • Sponsor: Parabilis Medicines, Inc. • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
First gene therapy for rare brain disorder begins testing in kids
Disease control Recruiting nowThis early-stage trial tests a gene therapy called Urbagen in 12 children aged 2-12 with CTNNB1 neurodevelopmental syndrome, a rare genetic condition causing motor and cognitive delays. The therapy is given as a single infusion into the brain fluid, along with immunosuppressant d…
Phase: PHASE1, PHASE2 • Sponsor: CTNNB1 Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a Parkinson's drug ease symptoms of a rare childhood brain condition?
Symptom relief Recruiting nowThis study tests whether L-dopa, a drug used for Parkinson's, can improve movement and communication in children with a rare genetic disorder called CTNNB1 syndrome. The condition causes developmental delays, muscle stiffness, and trouble walking. Seven children aged 1 to 15 will…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Dragonfly study launches to map rare genetic syndrome
Knowledge-focused Recruiting nowThe Dragonfly study is an international observational project tracking the development of 250 children and adults with CTNNB1 neurodevelopmental syndrome. Researchers will collect medical history, perform neurological exams, and use questionnaires to understand how symptoms and a…
Sponsor: University Medical Centre Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC